Antiviral Prophylaxis Against Hepatitis B Virus in Patients Treated with Anti-Tumor Necrosis Factor α Agents for Inflammatory Bowel Disease.
作者信息
Kang Eun Ae, Cheon Jae Hee
机构信息
Division of Gastroenterology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
出版信息
Gut Liver. 2022 Jul 15;16(4):501-502. doi: 10.5009/gnl220186.
Abstract
摘要
相似文献
1
Antiviral Prophylaxis Against Hepatitis B Virus in Patients Treated with Anti-Tumor Necrosis Factor α Agents for Inflammatory Bowel Disease.接受抗肿瘤坏死因子α制剂治疗的炎症性肠病患者的乙型肝炎病毒抗病毒预防
Gut Liver. 2022 Jul 15;16(4):501-502. doi: 10.5009/gnl220186.
2
Clinical Course of Hepatitis B Viral Infection in Patients Undergoing Anti-Tumor Necrosis Factor α Therapy for Inflammatory Bowel Disease.抗肿瘤坏死因子α治疗炎症性肠病患者乙型肝炎病毒感染的临床过程。
Gut Liver. 2022 May 15;16(3):396-403. doi: 10.5009/gnl210081.
3
Hepatitis B virus reactivation in HBsAg-positive patients with rheumatic diseases undergoing anti-tumor necrosis factor therapy or DMARDs.HBsAg 阳性的风湿性疾病患者在接受抗肿瘤坏死因子治疗或 DMARDs 治疗时乙型肝炎病毒再激活。
Int J Rheum Dis. 2013 Oct;16(5):527-31. doi: 10.1111/1756-185X.12154.
4
Impact of surveillance of hepatitis b and hepatitis c in patients with inflammatory bowel disease under anti-TNF therapies: multicenter prospective observational study (REPENTINA 3).抗TNF治疗下炎症性肠病患者中乙肝和丙肝监测的影响：多中心前瞻性观察研究（REPENTINA 3）
J Crohns Colitis. 2014 Nov;8(11):1529-38. doi: 10.1016/j.crohns.2014.06.009. Epub 2014 Jul 19.
5
Hepatitis B and inflammatory bowel disease: role of antiviral prophylaxis.乙型肝炎和炎症性肠病：抗病毒预防的作用。
World J Gastroenterol. 2013 Mar 7;19(9):1342-8. doi: 10.3748/wjg.v19.i9.1342.
6
Hepatitis B virus (HBV) reactivation in rheumatic patients with hepatitis core antigen (HBV occult carriers) undergoing anti-tumor necrosis factor therapy.风湿患者在接受肿瘤坏死因子治疗时，乙型肝炎病毒（HBV）再激活与乙型肝炎核心抗原（HBV 隐匿携带者）。
Clin Exp Rheumatol. 2013 Jan-Feb;31(1):118-21. Epub 2012 Oct 30.
7
Risk of hepatitis B reactivation during anti-TNF therapy; evaluation of patients with past hepatitis B infection.抗 TNF 治疗期间乙型肝炎再激活的风险；既往乙型肝炎感染患者的评估。
Turk J Gastroenterol. 2020 Jul;31(7):522-528. doi: 10.5152/tjg.2020.19295.
8
Risk of hepatitis B reactivation in patients receiving anti-tumor necrosis factor-α therapy.接受肿瘤坏死因子-α治疗的患者乙型肝炎病毒再激活的风险。
Int J Rheum Dis. 2021 Feb;24(2):254-259. doi: 10.1111/1756-185X.14034. Epub 2020 Nov 27.
9
Risk of hepatitis B virus reactivation in patients with autoimmune diseases undergoing non-tumor necrosis factor-targeted biologics.自身免疫性疾病患者在接受非肿瘤坏死因子靶向生物制剂治疗时乙型肝炎病毒再激活的风险。
World J Gastroenterol. 2021 May 21;27(19):2312-2324. doi: 10.3748/wjg.v27.i19.2312.
10
Hepatitis B reactivation and timing for prophylaxis.乙型肝炎再激活及预防时机。
World J Gastroenterol. 2015 Feb 21;21(7):2263-4. doi: 10.3748/wjg.v21.i7.2263.
引用本文的文献
1
Infectious complications in patients with inflammatory bowel disease in Asia: the results of a multinational web-based survey in the 8th Asian Organization for Crohn's and Colitis meeting.亚洲炎症性肠病患者的感染并发症：第八届亚洲克罗恩病和结肠炎组织会议上一项基于网络的多国调查结果
Intest Res. 2023 Jul;21(3):353-362. doi: 10.5217/ir.2023.00013. Epub 2023 Jul 27.
本文引用的文献
1
Update on the epidemiology of inflammatory bowel disease in Asia: where are we now?亚洲炎症性肠病流行病学的最新情况：我们目前处于什么阶段？
Intest Res. 2022 Apr;20(2):159-164. doi: 10.5217/ir.2021.00115. Epub 2022 Apr 29.
2
Natural history of inflammatory bowel disease: a comparison between the East and the West.炎症性肠病的自然史：东西方比较
Intest Res. 2022 Oct;20(4):418-430. doi: 10.5217/ir.2021.00104. Epub 2021 Dec 2.
3
Clinical Course of Hepatitis B Viral Infection in Patients Undergoing Anti-Tumor Necrosis Factor α Therapy for Inflammatory Bowel Disease.抗肿瘤坏死因子α治疗炎症性肠病患者乙型肝炎病毒感染的临床过程。
Gut Liver. 2022 May 15;16(3):396-403. doi: 10.5009/gnl210081.
4
Long-term Outcomes after the Discontinuation of Anti-Tumor Necrosis Factor-α Therapy in Patients with Inflammatory Bowel Disease under Clinical Remission: A Korean Association for the Study of Intestinal Disease Multicenter Study.炎症性肠病患者在临床缓解后停用抗肿瘤坏死因子-α治疗的长期结局：韩国肠病研究协会多中心研究。
Gut Liver. 2021 Sep 15;15(5):752-762. doi: 10.5009/gnl20233.
5
Prevention and management of viral hepatitis in inflammatory bowel disease: a clinical practice guideline by the Korean Association for the Study of Intestinal Diseases.炎症性肠病中病毒性肝炎的预防与管理：韩国肠道疾病研究协会临床实践指南
Intest Res. 2020 Jan;18(1):18-33. doi: 10.5217/ir.2019.09155. Epub 2020 Jan 30.
6
Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia.亚洲溃疡性结肠炎和克罗恩病免疫调节剂及生物制剂的最佳实践
Intest Res. 2019 Jul;17(3):285-310. doi: 10.5217/ir.2019.00026. Epub 2019 May 31.
7
The epidemiology of hepatitis B virus infection in Korea.韩国乙型肝炎病毒感染的流行病学。
Korean J Intern Med. 2019 Sep;34(5):945-953. doi: 10.3904/kjim.2019.007. Epub 2019 Mar 29.
8
Epidemiology of liver cancer in South Korea.韩国肝癌的流行病学。
Clin Mol Hepatol. 2018 Mar;24(1):1-9. doi: 10.3350/cmh.2017.0112. Epub 2017 Dec 18.
9
Can More Aggressive Treatment Improve Prognosis in Patients with Hepatocellular Carcinoma? A Direct Comparison of the Hong Kong Liver Cancer and Barcelona Clinic Liver Cancer Algorithms.更积极的治疗能否改善肝细胞癌患者的预后？香港肝癌和巴塞罗那临床肝癌算法的直接比较。
Gut Liver. 2018 Jan 15;12(1):94-101. doi: 10.5009/gnl17040.
10
Challenges in treating patients with inflammatory bowel disease and concurrent viral hepatitis infection.治疗炎症性肠病合并病毒性肝炎感染患者面临的挑战。
Expert Rev Gastroenterol Hepatol. 2016 Dec;10(12):1373-1383. doi: 10.1080/17474124.2016.1246181. Epub 2016 Oct 20.
Zotero 插件